CTI BioPharma Corp. (CTIC)

1.87
0.04 2.10
NASDAQ : Health Technology
Prev Close 1.91
Open 1.90
Day Low/High 1.85 / 1.92
52 Wk Low/High 1.70 / 5.36
Volume 180.58K
Avg Volume 410.60K
Exchange NASDAQ
Shares Outstanding 57.99M
Market Cap 111.92M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CTI BioPharma To Present At The Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

CTI BioPharma To Present At The Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

SEATTLE, Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp.

CTI BioPharma Reports Second Quarter 2018 Financial Results

CTI BioPharma Reports Second Quarter 2018 Financial Results

-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time-

CTI BioPharma To Report Second Quarter 2018 Financial Results On August 2, 2018

CTI BioPharma To Report Second Quarter 2018 Financial Results On August 2, 2018

SEATTLE, July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.

CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting With U.S. FDA

CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting With U.S. FDA

- Regulatory path to include Phase 3 trial expected to begin in 2019 -

Results Of Phase III (PIX306) Trial Evaluating Progression-Free Survival Of PIXUVRI® (pixantrone) Combined With Rituximab In Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Results Of Phase III (PIX306) Trial Evaluating Progression-Free Survival Of PIXUVRI® (pixantrone) Combined With Rituximab In Patients With Aggressive B-cell Non-Hodgkin Lymphoma

PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab

CTI BioPharma Announces The Continuation Without Modification Of PAC203 Phase 2 Study Of Pacritinib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

CTI BioPharma Announces The Continuation Without Modification Of PAC203 Phase 2 Study Of Pacritinib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

SEATTLE, July 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee (IDMC) of PAC203, the study will continue without modification and that a...

CTI BioPharma To Present At The JMP Securities 2018 Life Sciences Conference

CTI BioPharma To Present At The JMP Securities 2018 Life Sciences Conference

SEATTLE, June 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York, NY on Thursday, June 21, 2018 at 1:00 PM ET.

First Week Of CTIC July 20th Options Trading

First Week Of CTIC July 20th Options Trading

Investors in CTI BioPharma Corp saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

CTI BioPharma To Present At The Jefferies 2018 Global Healthcare Conference

CTI BioPharma To Present At The Jefferies 2018 Global Healthcare Conference

SEATTLE, June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host...

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Stocks with insider trader activity include LPNT, PATK and CTIC

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

Law Offices of Howard G. Smith reminds investors of the upcoming  April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Stocks with insider trader activity include SPTN, FL and CTIC

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Stocks with insider trader activity include ATRS, CMT and CTIC

Insider Trading Alert - DRE And CTIC Traded By Insiders

Insider Trading Alert - DRE And CTIC Traded By Insiders

Stocks with insider trader activity include DRE, CTIC and WAFD

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CTI BioPharma Corp.

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors Of Important Deadline In Class Action - CTIC

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors Of Important Deadline In Class Action - CTIC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp.

CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold for Himself

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold for Himself

In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CTI BioPharma Corp. - CTIC

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CTI BioPharma Corp. - CTIC

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CTI BioPharma Corp.

Kirby McInerney LLP Advises CTI BioPharma Corp. Investors Of Potential Claims

Kirby McInerney LLP Advises CTI BioPharma Corp. Investors Of Potential Claims

The law firm of Kirby McInerney LLP announced today that it has been retained by an investor to pursue claims against CTI BioPharma Corp.

3 Big Stocks You Should Stay Away From Right Now

3 Big Stocks You Should Stay Away From Right Now

Here's a technical look at how to trade some of the most active stocks on Wall Street right now.

INVESTOR ALERT: Investigation Of CTI BioPharma Corp. Announced By Law Offices Of Howard G. Smith

INVESTOR ALERT: Investigation Of CTI BioPharma Corp. Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces an investigation on behalf of investors of CTI BioPharma Corp.

3 Biotech Stocks Under $10 to Trade for Big Breakouts

3 Biotech Stocks Under $10 to Trade for Big Breakouts

These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.

TheStreet Quant Rating: E+ (Sell)